Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology

Open Access 20-04-2024 | Vulgar Psoriasis | Review

The Immunology of Psoriasis—Current Concepts in Pathogenesis

Authors: Izabela Sieminska, Monika Pieniawska, Tomasz M. Grzywa

Published in: Clinical Reviews in Allergy & Immunology

Login to get access

Abstract

Psoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the pathogenesis of psoriasis. Emerging evidence indicates that dendritic cells, TH17 cells, and keratinocytes constitute a pathogenic triad in psoriasis. Dendritic cells produce TNF-α and IL-23 to promote T cell differentiation toward TH17 cells that produce key psoriatic cytokines IL-17, IFN-γ, and IL-22. Their activity results in skin inflammation and activation and hyperproliferation of keratinocytes. In addition, other cells and signaling pathways are implicated in the pathogenesis of psoriasis, including TH9 cells, TH22 cells, CD8+ cytotoxic cells, neutrophils, γδ T cells, and cytokines and chemokines secreted by them. New insights from high-throughput analysis of lesional skin identified novel signaling pathways and cell populations involved in the pathogenesis. These studies not only expanded our knowledge about the mechanisms of immune response and the pathogenesis of psoriasis but also resulted in a revolution in the clinical management of patients with psoriasis. Thus, understanding the mechanisms of immune response in psoriatic inflammation is crucial for further studies, the development of novel therapeutic strategies, and the clinical management of psoriasis patients. The aim of the review was to comprehensively present the dysregulation of immune response in psoriasis with an emphasis on recent findings. Here, we described the role of immune cells, including T cells, B cells, dendritic cells, neutrophils, monocytes, mast cells, and innate lymphoid cells (ILCs), as well as non-immune cells, including keratinocytes, fibroblasts, endothelial cells, and platelets in the initiation, development, and progression of psoriasis.
Literature
1.
Armstrong AW, Read C (2020) Pathophysiology, Clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945–1960PubMedCrossRef
2.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, Global Psoriasis A (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590-mCrossRef
3.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ et al (2016) Psoriasis Nature Reviews Disease Primers 2:16082PubMedCrossRef
4.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76:377–390PubMedPubMedCentralCrossRef
5.
6.
7.
Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M et al (2017) Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun 8:15382PubMedPubMedCentralCrossRef
8.
9.
Swindell WR, Johnston A, Voorhees JJ, Elder JT, Gudjonsson JE (2013) Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics 14:527PubMedPubMedCentralCrossRef
10.
Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP et al (2010) Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 130:1829–1840PubMedPubMedCentralCrossRef
11.
Kabashima K, Honda T, Ginhoux F, Egawa G (2019) The immunological anatomy of the skin. Nat Rev Immunol 19:19–30PubMedCrossRef
12.
Ho AW, Kupper TS (2019) T cells and the skin: from protective immunity to inflammatory skin disorders. Nat Rev Immunol 19:490–502PubMedCrossRef
13.
14.
Quaresma JAS (2019) Organization of the skin immune system and compartmentalized immune responses in infectious diseases. Clin Microbiol Rev 32:e00034-e118PubMedPubMedCentralCrossRef
15.
Clark RA (2010) Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 130:362–370PubMedCrossRef
16.
17.
18.
Zhang LJ, Sen GL, Ward NL, Johnston A, Chun K, Chen Y et al (2016) Antimicrobial peptide LL37 and MAVS signaling drive interferon-β production by epidermal keratinocytes during skin injury. Immunity 45:119–130PubMedPubMedCentralCrossRef
19.
Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B et al (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564–569PubMedCrossRef
20.
Liu S, Wu F, Wu Z, Li Y, Zhang S, Yu N (2019) IL-17A synergistically enhances TLR3-mediated IL-36γ production by keratinocytes: a potential role in injury-amplified psoriatic inflammation. Exp Dermatol 28:233–239PubMedCrossRef
21.
Re F, Strominger JL (2001) Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276:37692–37699PubMedCrossRef
22.
Ramirez-Carrozzi V, Sambandam A, Luis E, Lin Z, Jeet S, Lesch J et al (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12:1159–1166PubMedCrossRef
23.
Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1–23PubMedCrossRef
24.
25.
Wang A, Fogel AL, Murphy MJ, Panse G, McGeary MK, McNiff JM et al (2021) Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis. JID Innovations 1:100021PubMedPubMedCentralCrossRef
26.
27.
Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE (2014) Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol 171:97–107PubMedPubMedCentralCrossRef
28.
Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A et al (2014) Transcriptome analysis of psoriasis in a large case–control sample: RNA-seq provides insights into disease mechanisms. J Investig Dermatol 134:1828–1838PubMedCrossRef
29.
Natsuaki Y, Egawa G, Nakamizo S, Ono S, Hanakawa S, Okada T et al (2014) Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat Immunol 15:1064–1069PubMedCrossRef
30.
Mee JB, Johnson CM, Morar N, Burslem F, Groves RW (2007) The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 171:32–42PubMedPubMedCentralCrossRef
31.
Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y et al (2019) A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol 139:146–156PubMedCrossRef
32.
Iznardo H, Puig L (2021) The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol 17:187–199PubMedCrossRef
33.
Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N et al (2014) IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol 134:2757–2767PubMedCrossRef
34.
Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701–705PubMedCrossRef
35.
36.
Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752–759PubMedCrossRef
37.
Hochrein H, O’Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, Shortman K (2000) Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 192:823–833PubMedPubMedCentralCrossRef
38.
Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT et al (1989) Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86:6367–6371PubMedPubMedCentralCrossRef
39.
Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD (2009) IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183:3170–3176PubMedCrossRef
40.
Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M et al (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29:628–636PubMedCrossRef
41.
Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:201561CrossRef
42.
Szepietowski JC, Bielicka E, Nockowski P, Noworolska A, Wasik F (2000) Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity. Clin Exp Dermatol 25:643–647PubMedCrossRef
43.
Bonifati C, Trento E, Cordiali-Fei P, Carducci M, Mussi A, D’Auria L et al (1997) Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. Clin Immunol Immunopathol 83:41–44PubMedCrossRef
44.
Adachi T, Kobayashi T, Sugihara E, Yamada T, Ikuta K, Pittaluga S et al (2015) Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. Nat Med 21:1272–1279PubMedPubMedCentralCrossRef
45.
Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M (2001) Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 26:119–124PubMedCrossRef
46.
Schulz BS, Michel G, Wagner S, Süss R, Beetz A, Peter RU et al (1993) Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 151:4399–406PubMedCrossRef
47.
Giustizieri ML, Mascia F, Frezzolini A, De Pità O, Chinni LM, Giannetti A et al (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107:871–877PubMedCrossRef
48.
Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang X-J, Wolf P (2013) Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS ONE 8:e51752PubMedPubMedCentralCrossRef
49.
Midde HS, Priyadarssini M, Rajappa M, Munisamy M, Mohan Raj PS, Singh S, Priyadarshini G (2021) Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis. Clin Exp Dermatol 46:50–7PubMedCrossRef
50.
Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I et al (2006) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology 46:417–425PubMedCrossRef
51.
Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Investig 104:1527–1537PubMedPubMedCentralCrossRef
52.
Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR (1998) Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111:1053–1057PubMedCrossRef
53.
Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199:125–130PubMedPubMedCentralCrossRef
54.
Swindell WR, Xing X, Stuart PE, Chen CS, Aphale A, Nair RP et al (2012) Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS ONE 7:e34594PubMedPubMedCentralCrossRef
55.
de Jesús-Gil C, Ruiz-Romeu E, Ferran M, Sagristà M, Chiriac A, García P et al (2020) IL-15 and IL-23 synergize to trigger Th17 response by CLA+ T cells in psoriasis. Exp Dermatol 29:630–638PubMedCrossRef
56.
Purzycka-Bohdan D, Szczerkowska-Dobosz A, Zablotna M, Wierzbicka J, Piotrowska A, Zmijewski MA et al (2016) Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease. PloS One 11:e0165577-eCrossRef
57.
Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160:319–324PubMedCrossRef
58.
Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950–957PubMedCrossRef
59.
Liu Y, Zhang C, Li B, Yu C, Bai X, Xiao C et al (2021) A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis. J Dermatol Sci 101:84–92PubMedCrossRef
60.
Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N et al (2019) Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol 139:1480–1489PubMedPubMedCentralCrossRef
61.
Tollenaere MAX, Hebsgaard J, Ewald DA, Lovato P, Garcet S, Li X et al (2021) Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways. Br J Dermatol 185:585–594PubMedPubMedCentralCrossRef
62.
Ohta Y, Hamada Y, Katsuoka K (2001) Expression of IL-18 in psoriasis. Arch Dermatol Res 293:334–342PubMedCrossRef
63.
Gangemi S, Merendino RA, Guarneri F, Minciullo PL, DiLorenzo G, Pacor M, Cannavò SP (2003) Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations. J Eur Acad Dermatol Venereol 17:42–46PubMedCrossRef
64.
Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian Y-W, Bivi N et al (2019) Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep 9:5211PubMedPubMedCentralCrossRef
65.
He Z, Jin L, Liu ZF, Hu L, Dang EL, Feng ZZ et al (2012) Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol 167:191–193PubMedCrossRef
66.
Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M et al (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454:350–352PubMedPubMedCentralCrossRef
67.
Wang Y, Wang LL, Yang HY, Wang FF, Zhang XX, Bai YP (2016) Interleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cells. Am J Transl Res 8:3188–3196PubMedPubMedCentral
68.
Wei L, Laurence A, Elias KM, O’Shea JJ (2007) IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282:34605–34610PubMedCrossRef
69.
Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W (2007) Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648–651PubMedCrossRef
70.
Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:1373–1383PubMedCrossRef
71.
Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864–871PubMedCrossRef
72.
Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M (2015) Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol 136:351–9.e1PubMedCrossRef
73.
Luan L, Ding Y, Han S, Zhang Z, Liu X (2014) An increased proportion of circulating Th22 and Tc22 cells in psoriasis. Cell Immunol 290:196–200PubMedCrossRef
74.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910–1914PubMedCrossRef
75.
76.
Wang Y, Edelmayer R, Wetter J, Salte K, Gauvin D, Leys L et al (2019) Monocytes/macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation. Sci Rep 9:5310PubMedPubMedCentralCrossRef
77.
Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S et al (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577–2587PubMedPubMedCentralCrossRef
78.
Kumari S, Bonnet MC, Ulvmar MH, Wolk K, Karagianni N, Witte E et al (2013) Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity 39:899–911PubMedCrossRef
79.
Kunz S, Wolk K, Witte E, Witte K, Doecke W-D, Volk H-D et al (2006) Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 15:991–1004PubMedCrossRef
80.
Xu M, Lu H, Lee YH, Wu Y, Liu K, Shi Y et al (2018) An interleukin-25-mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation. Immunity 48:787–98.e4PubMedCrossRef
81.
Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM et al (2019) Biological effects of IL-26 on T cell–mediated skin inflammation, including psoriasis. J Investig Dermatol 139:878–889PubMedCrossRef
82.
Hatano R, Itoh T, Otsuka H, Okamoto S, Komiya E, Iwata S et al (2019) Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. MAbs 11:1428–1442PubMedPubMedCentralCrossRef
83.
Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A et al (2012) IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 21:892–894PubMedCrossRef
84.
Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL et al (2011) IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 186:2613–2622PubMedCrossRef
85.
D’Erme AM, Wilsmann-Theis D, Wagenpfeil J, Hölzel M, Ferring-Schmitt S, Sternberg S et al (2015) IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 135:1025–1032PubMedCrossRef
86.
Tortola L, Rosenwald E, Abel B, Blumberg H, Schäfer M, Coyle AJ et al (2012) Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 122:3965–3976PubMedPubMedCentralCrossRef
87.
Teng X, Hu Z, Wei X, Wang Z, Guan T, Liu N et al (2014) IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol 192:1815–1823PubMedCrossRef
88.
Rønholt K, Nielsen AL, Johansen C, Vestergaard C, Fauerbye A, López-Vales R et al (2020) IL-37 expression is downregulated in lesional psoriasis skin. Immunohorizons 4:754–761PubMedCrossRef
89.
Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ, Doti N, Pagnanelli G et al (2018) IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis 9:1104PubMedPubMedCentralCrossRef
90.
Han Y, Mora J, Huard A, da Silva P, Wiechmann S, Putyrski M et al (2019) IL-38 ameliorates skin inflammation and limits IL-17 production from γδ T cells. Cell Rep 27:835–46.e5PubMedCrossRef
91.
Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202:135–143PubMedPubMedCentralCrossRef
92.
Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, Ødum N (2005) Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 125:936–944PubMedCrossRef
93.
Tohyama M, Yang L, Hanakawa Y, Dai X, Shirakata Y, Sayama K (2012) IFN-α enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J Invest Dermatol 132:1933–1935PubMedCrossRef
94.
Bielenberg DR, McCarty MF, Bucana CD, Yuspa SH, Morgan D, Arbeit JM et al (1999) Expression of interferon-beta is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 112:802–809PubMedCrossRef
95.
Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X et al (2017) IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep 7:13831PubMedPubMedCentralCrossRef
96.
Li AG, Wang D, Feng XH, Wang XJ (2004) Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23:1770–1781PubMedPubMedCentralCrossRef
97.
Di Fusco D, Laudisi F, Dinallo V, Monteleone I, Di Grazia A, Marafini I et al (2017) Smad7 positively regulates keratinocyte proliferation in psoriasis. Br J Dermatol 177:1633–1643PubMedCrossRef
98.
Flisiak I, Porębski P, Flisiak R, Chodynicka B (2003) Plasma transforming growth factor β1 as a biomarker of psoriasis activity and treatment efficacy. Biomarkers 8:437–443PubMedCrossRef
99.
Flisiak I, Chodynicka B, Porebski P, Flisiak R (2002) Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 19:121–125PubMedCrossRef
100.
Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D et al (1997) Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11:115–118PubMed
101.
Patel AB, Tsilioni I, Weng Z, Theoharides TC (2018) TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. Exp Dermatol 27:135–143PubMedCrossRef
102.
Haider AS, Cohen J, Fei J, Zaba LC, Cardinale I, Toyoko K et al (2008) Insights into gene modulation by therapeutic TNF and IFNγ antibodies: TNF regulates IFNγ production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Investig Dermatol 128:655–666PubMedCrossRef
103.
Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M et al (2006) Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176:1431–1438PubMedCrossRef
104.
Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102:19057–19062PubMedPubMedCentralCrossRef
105.
Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G et al (2015) Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 212:2203–2212PubMedPubMedCentralCrossRef
106.
Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V et al (2009) Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206:1983–1994PubMedPubMedCentralCrossRef
107.
Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I et al (2011) Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131:677–687PubMedCrossRef
108.
Liu T, Li S, Ying S, Tang S, Ding Y, Li Y et al (2020) The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 11:594735PubMedPubMedCentralCrossRef
109.
McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM et al (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10:314–324PubMedPubMedCentralCrossRef
110.
Haines CJ, Chen Y, Blumenschein WM, Jain R, Chang C, Joyce-Shaikh B et al (2013) Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep 3:1378–1388PubMedCrossRef
111.
Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedPubMedCentralCrossRef
112.
Whitley SK, Li M, Kashem SW, Hirai T, Igyártó BZ, Knizner K et al (2022) Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells. Sci Immunol 7:eabq3254PubMedPubMedCentralCrossRef
113.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141PubMedPubMedCentralCrossRef
114.
115.
Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513–3521PubMedCrossRef
116.
Kawaguchi M, Kokubu F, Odaka M, Watanabe S, Suzuki S, Ieki K et al (2004) Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. J Allergy Clin Immunol 114:444–450PubMedCrossRef
117.
Albanesi C, Cavani A, Girolomoni G (1999) IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 162:494–502PubMedCrossRef
118.
Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM et al (2013) Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 190:2252–2262PubMedCrossRef
119.
Ha H-L, Wang H, Pisitkun P, Kim J-C, Tassi I, Tang W et al (2014) IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci 111:E3422–E3431PubMedPubMedCentralCrossRef
120.
Ehst B, Wang Z, Leitenberger J, McClanahan D, De La Torre R, Sawka E et al (2021) Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytes. Cytokine 138:155357PubMedCrossRef
121.
Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM et al (2014) IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE 9:e90284PubMedPubMedCentralCrossRef
122.
Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Li K, Tian S et al (2016) Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol 174:136–145PubMedCrossRef
123.
Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC et al (2008) IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 181:8504–8512PubMedCrossRef
124.
Rauschenberger T, Schmitt V, Azeem M, Klein-Hessling S, Murti K, Grän F et al (2019) T cells control chemokine secretion by keratinocytes. Front Immunol 10:1917PubMedPubMedCentralCrossRef
125.
Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, Arreaza M et al (2010) Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 302:113–123PubMedCrossRef
126.
Vestergaard C, Just H, Baumgartner Nielsen J, Thestrup-Pedersen K, Deleuran M (2004) Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm Venereol 84:353–8PubMedCrossRef
127.
Teraki Y, Miyake A, Takebayashi R, Shiohara T (2004) Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 29:658–663PubMedCrossRef
128.
de Groot M, Teunissen MB, Ortonne JP, Lambert JR, Naeyaert JM, Picavet DI et al (2007) Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res 299:305–313PubMedPubMedCentralCrossRef
129.
Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DYM (2003) Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 112:1195–1202PubMedCrossRef
130.
Johansen C, Rittig AH, Mose M, Bertelsen T, Weimar I, Nielsen J et al (2017) STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes. PLoS ONE 12:e0176994PubMedPubMedCentralCrossRef
131.
Bosè F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A et al (2013) Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis. Am J Pathol 183:413–421PubMedCrossRef
132.
Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164:6621–6632PubMedCrossRef
133.
Gombert M, Dieu-Nosjean M-C, Winterberg F, Bünemann E, Kubitza RC, Da Cunha L et al (2005) CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 174:5082–5091PubMedCrossRef
134.
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I et al (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129:2175–2183PubMedPubMedCentralCrossRef
135.
Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES et al (2003) Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol 170:4638–4648PubMedCrossRef
136.
Kim HO, Cho SI, Chung BY, Ahn HK, Park CW, Lee CH (2012) Expression of CCL1 and CCL18 in atopic dermatitis and psoriasis. Clin Exp Dermatol 37:521–526PubMedCrossRef
137.
Homey B, Alenius H, Müller A, Soto H, Bowman EP, Yuan W et al (2002) CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 8:157–165PubMedCrossRef
138.
Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H et al (2003) Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 111:592–597PubMedCrossRef
139.
Kulke R, Bornscheuer E, Schlüter C, Bartels J, Röwert J, Sticherling M, Christophers E (1998) The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110:90–94PubMedCrossRef
140.
Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132:2552–2564PubMedPubMedCentralCrossRef
141.
Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG (2001) Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81:335–347PubMedCrossRef
142.
Zgraggen S, Huggenberger R, Kerl K, Detmar M (2014) An important role of the SDF-1/CXCR4 axis in chronic skin inflammation. PloS One 9:e93665-eCrossRef
143.
Fraticelli P, Sironi M, Bianchi G, D’Ambrosio D, Albanesi C, Stoppacciaro A et al (2001) Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107:1173–1181PubMedPubMedCentralCrossRef
144.
Christophers E, Metzler G, Röcken M (2014) Bimodal immune activation in psoriasis. Br J Dermatol 170:59–65PubMedCrossRef
145.
Németh T, Sperandio M, Mócsai A (2020) Neutrophils as emerging therapeutic targets. Nat Rev Drug Discovery 19:253–275PubMedCrossRef
146.
Rodriguez-Rosales YA, Langereis JD, Gorris MAJ, van den Reek JMPA, Fasse E, Netea MG et al (2021) Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. Journal of Allergy and Clinical Immunology 148:1030–1040PubMedCrossRef
147.
Katayama H (2018) Development of psoriasis by continuous neutrophil infiltration into the epidermis. Exp Dermatol 27:1084–1091PubMedCrossRef
148.
Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, Madonna S et al (2009) Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 206:249–258PubMedPubMedCentralCrossRef
149.
Senra L, Mylonas A, Kavanagh RD, Fallon PG, Conrad C, Borowczyk-Michalowska J et al (2019) IL-17E (IL-25) enhances innate immune responses during skin inflammation. J Invest Dermatol 139:1732–42.e17PubMedCrossRef
150.
Shao S, Fang H, Zhang J, Jiang M, Xue K, Ma J et al (2019) Neutrophil exosomes enhance the skin autoinflammation in generalized pustular psoriasis via activating keratinocytes. Faseb j 33:6813–6828PubMedCrossRef
151.
Liu XT, Shi ZR, Lu SY, Hong D, Qiu XN, Tan GZ et al (2022) Enhanced migratory ability of neutrophils toward epidermis contributes to the development of psoriasis via crosstalk with keratinocytes by releasing IL-17A. Front Immunol 13:817040PubMedPubMedCentralCrossRef
152.
Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S et al (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187:490–500PubMedCrossRef
153.
Guérard S, Allaeys I, Martin G, Pouliot R, Poubelle PE (2013) Psoriatic keratinocytes prime neutrophils for an overproduction of superoxide anions. Arch Dermatol Res 305:879–889PubMedCrossRef
154.
Hu SC-S, Yu H-S, Yen F-L, Lin C-L, Chen G-S, Lan C-CE (2016) Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes. Sci Rep 6:31119PubMedPubMedCentralCrossRef
155.
Skrzeczynska-Moncznik J, Zabieglo K, Osiecka O, Morytko A, Brzoza P, Drozdz L et al (2020) Differences in staining for neutrophil elastase and its controlling inhibitor SLPI reveal heterogeneity among neutrophils in psoriasis. J Invest Dermatol 140:1371–8.e3PubMedCrossRef
156.
Herster F, Bittner Z, Archer NK, Dickhöfer S, Eisel D, Eigenbrod T et al (2020) Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis. Nat Commun 11:105PubMedPubMedCentralCrossRef
157.
Shao S, Fang H, Dang E, Xue K, Zhang J, Li B et al (2019) Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front Immunol 10:746PubMedPubMedCentralCrossRef
158.
Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, Van Rooijen N et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114PubMedPubMedCentralCrossRef
159.
Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K et al (2006) Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116:2094–2104PubMedPubMedCentralCrossRef
160.
Terhorst D, Chelbi R, Wohn C, Malosse C, Tamoutounour S, Jorquera A et al (2015) Dynamics and transcriptomics of skin dendritic cells and macrophages in an imiquimod-induced, biphasic mouse model of psoriasis. J Immunol 195:4953–4961PubMedCrossRef
161.
Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, Nograles KE, Pierson KC, Mitsui H et al (2010) A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Investig Dermatol 130:2412–2422PubMedCrossRef
162.
Erbel C, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L et al (2014) IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 193:4344–4355PubMedPubMedCentralCrossRef
163.
Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C et al (2021) Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol 141:1707–18.e9PubMedCrossRef
164.
Reynolds G, Vegh P, Fletcher J, Poyner EFM, Stephenson E, Goh I, Botting RA, Huang N, Olabi B, Dubois A, Dixon D, Green K, Maunder D, Engelbert J, Efremova M, Polański K, Jardine L, Jones C, Ness T, Horsfall D, McGrath J, Carey C, Popescu DM, Webb S, Wang XN, Sayer B, Park JE, Negri VA, Belokhvostova D, Lynch MD, McDonald D, Filby A, Hagai T, Meyer KB, Husain A, Coxhead J, Vento-Tormo R, Behjati S, Lisgo S, Villani AC, Bacardit J, Jones PH, O’Toole EA, Ogg GS, Rajan N, Reynolds NJ, Teichmann SA, Watt FM, Haniffa M (2021) Developmental cell programs are co-opted in inflammatory skin disease. Science 371(6527):eaba6500. https://​doi.​org/​10.​1126/​science.​aba6500CrossRefPubMedPubMedCentral
165.
166.
167.
Galli SJ, Gaudenzio N, Tsai M (2020) Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol 38:49–77PubMedCrossRef
168.
Harvima IT, Nilsson G, Suttle MM, Naukkarinen A (2008) Is there a role for mast cells in psoriasis? Arch Dermatol Res 300:461–478PubMedCrossRef
169.
170.
171.
Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC (2004) Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 150:852–859PubMedCrossRef
172.
Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A (2006) CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 36:118–128PubMedCrossRef
173.
174.
Cameron AL, Kirby B, Griffiths CE (2003) Circulating natural killer cells in psoriasis. Br J Dermatol 149:160–164PubMedCrossRef
175.
Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM et al (2000) Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 165:4076–4085PubMedCrossRef
176.
Bielecki P, Riesenfeld SJ, Hütter J-C, Torlai Triglia E, Kowalczyk MS, Ricardo-Gonzalez RR et al (2021) Skin-resident innate lymphoid cells converge on a pathogenic effector state. Nature 592:128–32PubMedPubMedCentralCrossRef
177.
178.
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC et al (2009) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:79–88PubMedCrossRef
179.
Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J et al (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:3183–3194PubMedPubMedCentralCrossRef
180.
Martini E, Wikén M, Cheuk S, Gallais Sérézal I, Baharom F, Ståhle M et al (2017) Dynamic changes in resident and infiltrating epidermal dendritic cells in active and resolved psoriasis. J Invest Dermatol 137:865–73PubMedCrossRef
181.
Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M et al (2011) Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses. Journal of Allergy and Clinical Immunology 127:787–94.e9PubMedCrossRef
182.
Cheng JB, Sedgewick AJ, Finnegan AI, Harirchian P, Lee J, Kwon S et al (2018) Transcriptional programming of normal and inflamed human epidermis at single-cell resolution. Cell Rep 25:871–883PubMedPubMedCentralCrossRef
183.
Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5:919–923PubMedCrossRef
184.
Suzuki T, Hirakawa S, Shimauchi T, Ito T, Sakabe J-I, Detmar M, Tokura Y (2014) VEGF-A promotes IL-17A-producing γδ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci 74:116–124PubMedCrossRef
185.
Wohn C, Ober-Blöbaum JL, Haak S, Pantelyushin S, Cheong C, Zahner SP et al (2013) Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci 110:10723–10728PubMedPubMedCentralCrossRef
186.
Zhou Y, Xu F, Chen XY, Yan BX, Wang ZY, Chen SQ et al (2022) The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry. Cell Mol Immunol 19:1400–1413PubMedPubMedCentralCrossRef
187.
Borek I, Köffel R, Feichtinger J, Spies M, Glitzner-Zeis E, Hochgerner M et al (2020) BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells. J Allergy Clin Immunol 145:1194–207.e11PubMedCrossRef
188.
Yoshiki R, Kabashima K, Honda T, Nakamizo S, Sawada Y, Sugita K et al (2014) IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. J Invest Dermatol 134:1912–1921PubMedCrossRef
189.
Zheng T, Zhao W, Li H, Xiao S, Hu R, Han M et al (2018) p38α signaling in Langerhans cells promotes the development of IL-17–producing T cells and psoriasiform skin inflammation. Sci Signal 11:eaao1685PubMedCrossRef
190.
Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, Kupper TS (2006) The vast majority of CLA+ T cells are resident in normal skin. J Immunol 176:4431–4439PubMedCrossRef
191.
Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, Eidsmo L (2014) Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 192:3111–3120PubMedPubMedCentralCrossRef
192.
Orlik C, Deibel D, Küblbeck J, Balta E, Ganskih S, Habicht J et al (2020) Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. Cell Mol Immunol 17:380–394PubMedCrossRef
193.
Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A et al (2007) α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13:836–842PubMedCrossRef
194.
Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5:e14108PubMedPubMedCentralCrossRef
195.
196.
Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F (2009) Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 10:857–863PubMedCrossRef
197.
Solberg SM, Aarebrot AK, Sarkar I, Petrovic A, Sandvik LF, Bergum B et al (2021) Mass cytometry analysis of blood immune cells from psoriasis patients on biological therapy. Eur J Immunol 51:694–702PubMedCrossRef
198.
Hirahara K, Ghoreschi K, Laurence A, Yang X-P, Kanno Y, O’Shea JJ (2010) Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21:425–434PubMedPubMedCentralCrossRef
199.
Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al (2006) The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133PubMedCrossRef
200.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C et al (2021) Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nat Commun 12:4741PubMedPubMedCentralCrossRef
201.
Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207–1211PubMedCrossRef
202.
Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A et al (2013) Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 15:R136-RCrossRef
203.
Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L et al (2008) Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 181:4733–4741PubMedCrossRef
204.
Chang H-W, Yan D, Singh R, Liu J, Lu X, Ucmak D et al (2018) Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome 6:154PubMedPubMedCentralCrossRef
205.
Ruiz-Romeu E, Ferran M, de Jesús-Gil C, García P, Sagristà M, Casanova JM et al (2018) Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A. J Invest Dermatol 138:580–587PubMedCrossRef
206.
207.
Wolk K, Witte K, Witte E, Raftery M, Kokolakis G, Philipp S et al (2013) IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med 5:204ra129PubMedCrossRef
208.
Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279PubMedPubMedCentralCrossRef
209.
Le ST, Merleev AA, Luxardi G, Shimoda M, Adamopoulos IE, Tsoi LC et al (2019) 2D visualization of the psoriasis transcriptome fails to support the existence of dual-secreting IL-17A/IL-22 Th17 T cells. Front Immunol 10:589PubMedPubMedCentralCrossRef
210.
Basu R, O’Quinn Darrell B, Silberger Daniel J, Schoeb Trenton R, Fouser L, Ouyang W et al (2012) Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 37:1061–75PubMedPubMedCentralCrossRef
211.
212.
Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE et al (2014) Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med 6:219ra8-ra8PubMedPubMedCentralCrossRef
213.
Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M et al (2015) IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 112:2163–2168PubMedPubMedCentralCrossRef
214.
Onderdijk AJ, Baerveldt EM, Kurek D, Kant M, Florencia EF, Debets R, Prens EP (2015) IL-4 downregulates IL-1β and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine. J Immunol 195:1744–1752PubMedCrossRef
215.
216.
Wang Y, Wang L, Yang H, Yuan W, Ren J, Bai Y (2016) Activated circulating T follicular helper cells are associated with disease severity in patients with psoriasis. J Immunol Res 2016:7346030PubMedPubMedCentralCrossRef
217.
Niu J, Song Z, Yang X, Zhai Z, Zhong H, Hao F (2015) Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis. J Eur Acad Dermatol Venereol 29:1791–6PubMedCrossRef
218.
Liu J, Chang H-W, Huang Z-M, Nakamura M, Sekhon S, Ahn R et al (2021) Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. Journal of Allergy and Clinical Immunology 147:2370–2380PubMedCrossRef
219.
Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH (2021) Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol 22:809–819PubMedPubMedCentralCrossRef
220.
Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJ, Kupper TS et al (2013) CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol 133:973–979PubMedCrossRef
221.
Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, de Rie MA et al (2014) The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 134:2898–2907PubMedCrossRef
222.
Di Meglio P, Villanova F, Navarini AA, Mylonas A, Tosi I, Nestle FO, Conrad C (2016) Targeting CD8+ T cells prevents psoriasis development. J Allergy Clin Immunol 138:274–6.e6PubMedCrossRef
223.
Ribot JC, Lopes N, Silva-Santos B (2021) γδ T cells in tissue physiology and surveillance. Nat Rev Immunol 21:221–232PubMedCrossRef
224.
Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Becher B (2012) Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest 122:2252–2256PubMedPubMedCentralCrossRef
225.
226.
Matos TR, O’Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS et al (2017) Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest 127:4031–4041PubMedPubMedCentralCrossRef
227.
Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N et al (2011) Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 187:2783–2793PubMedCrossRef
228.
Nussbaum L, Chen YL, Ogg GS (2021) Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol 184:14–24PubMedCrossRef
229.
Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR et al (2005) Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174:164–173PubMedCrossRef
230.
Yang L, Li B, Dang E, Jin L, Fan X, Wang G (2016) Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci 81:85–92PubMedCrossRef
231.
Sivasami P, Elkins C, Diaz-Saldana PP, Goss K, Peng A, Hamersky MIV et al (2023) Obesity-induced dysregulation of skin-resident PPAR&γ+ Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 56:1844–61.e6PubMedCrossRef
232.
Yan K, Xu W, Huang Y, Zhang Z, Huang Q, Xin KZ et al (2018) Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway. Br J Dermatol 179:896–905PubMedCrossRef
233.
Zhao M, Wang LT, Liang GP, Zhang P, Deng XJ, Tang Q et al (2014) Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol 150:22–30PubMedCrossRef
234.
Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C et al (2015) Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med 7:279ra39-ra39PubMedPubMedCentralCrossRef
235.
Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ et al (2017) Human Tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep 20:2921–2934PubMedPubMedCentralCrossRef
236.
Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN et al (2012) Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A 109:7037–7042PubMedPubMedCentralCrossRef
237.
238.
Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL et al (2021) Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol 73:1220–32PubMedPubMedCentralCrossRef
239.
Kurihara K, Fujiyama T, Phadungsaksawasdi P, Ito T, Tokura Y (2019) Significance of IL-17A-producing CD8(+)CD103(+) skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course. J Dermatol Sci 95:21–27PubMedCrossRef
240.
Masson Regnault M, Konstantinou M-P, Khemis A, Poulin Y, Bourcier M, Amelot F et al (2017) Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol 31:1491–6PubMedCrossRef
241.
242.
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y et al (2023) Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). The Lancet 401:38–48CrossRef
243.
Fujiyama T, Umayahara T, Kurihara K, Shimauchi T, Ito T, Aoshima M et al (2020) Skin infiltration of pathogenic migratory and resident T cells is decreased by secukinumab treatment in psoriasis. J Invest Dermatol 140:2073–6.e6PubMedCrossRef
244.
Hartwig T, Pantelyushin S, Croxford AL, Kulig P, Becher B (2015) Dermal IL-17-producing γδ T cells establish long-lived memory in the skin. Eur J Immunol 45:3022–3033PubMedCrossRef
245.
Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NVC, Jenisch S et al (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827–851PubMedPubMedCentralCrossRef
246.
Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C et al (2014) The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 5:5621PubMedCrossRef
247.
Minns D, Smith KJ, Alessandrini V, Hardisty G, Melrose L, Jackson-Jones L et al (2021) The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation. Nat Commun 12:1285PubMedPubMedCentralCrossRef
248.
Fuentes-Duculan J, Bonifacio KM, Hawkes JE, Kunjravia N, Cueto I, Li X et al (2017) Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Exp Dermatol 26:1075–1082PubMedPubMedCentralCrossRef
249.
Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL et al (2016) Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med 213:2399–2412PubMedPubMedCentralCrossRef
250.
Bourgeois EA, Subramaniam S, Cheng TY, De Jong A, Layre E, Ly D et al (2015) Bee venom processes human skin lipids for presentation by CD1a. J Exp Med 212:149–163PubMedPubMedCentralCrossRef
251.
Kim JH, Hu Y, Yongqing T, Kim J, Hughes VA, Le Nours J et al (2016) CD1a on Langerhans cells controls inflammatory skin disease. Nat Immunol 17:1159–1166PubMedPubMedCentralCrossRef
252.
253.
254.
Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG (2015) Deep sequencing of the T-cell Receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis. F1000Res 4:460PubMedPubMedCentralCrossRef
255.
Debes GF, McGettigan SE (2019) Skin-associated B cells in health and inflammation. J Immunol 202:1659–1666PubMedCrossRef
256.
Lu J, Ding Y, Yi X, Zheng J (2016) CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity. Braz J Med Biol Res 49:e5374-eCrossRef
257.
Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Xiangyu P, Kunjravia N et al (2016) Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. Journal of Allergy and Clinical Immunology 137:118–29.e5PubMedCrossRef
258.
Guarneri C, Aguennouz M, Guarneri F, Polito F, Benvenga S, Cannavò SP (2018) Autoimmunity to heterogeneous nuclear ribonucleoprotein A1 in psoriatic patients and correlation with disease severity. J Dtsch Dermatol Ges 16:1103–1107PubMed
259.
Jones DA, Yawalkar N, Suh KY, Sadat S, Rich B, Kupper TS (2004) Identification of autoantigens in psoriatic plaques using expression cloning. J Invest Dermatol 123:93–100PubMedCrossRef
260.
Yuan Y, Qiu J, Lin ZT, Li W, Haley C, Mui UN et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol 71:941–951PubMedCrossRef
261.
Mizumaki K, Horii M, Kano M, Komuro A, Matsushita T (2021) Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells. Sci Rep 11:2106PubMedPubMedCentralCrossRef
262.
Yanaba K, Kamata M, Ishiura N, Shibata S, Asano Y, Tada Y et al (2013) Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J Leukoc Biol 94:563–573PubMedPubMedCentralCrossRef
263.
Benhadou F, Mintoff D, Del Marmol V (2019) Psoriasis: keratinocytes or immune cells - which is the trigger? Dermatology 235:91–100PubMedCrossRef
264.
Albanesi C, Madonna S, Gisondi P, Girolomoni G (2018) The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol 9:1549PubMedPubMedCentralCrossRef
265.
266.
Kim TG, Jee H, Fuentes-Duculan J, Wu WH, Byamba D, Kim DS et al (2014) Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J Invest Dermatol 134:1462–1465PubMedCrossRef
267.
Pène J, Chevalier S, Preisser L, Vénéreau E, Guilleux MH, Ghannam S et al (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180:7423–7430PubMedCrossRef
268.
Mabuchi T, Takekoshi T, Hwang ST (2011) Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 187:5026–5031PubMedCrossRef
269.
Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Newland D, Wang Y et al (2017) IL-17-Secreting γδ T cells are completely dependent upon CCR6 for homing to inflamed skin. J Immunol 199:3129–3136PubMedCrossRef
270.
Müller A, Hennig A, Lorscheid S, Grondona P, Schulze-Osthoff K, Hailfinger S, Kramer D (2018) IκBζ is a key transcriptional regulator of IL-36–driven psoriasis-related gene expression in keratinocytes. Proc Natl Acad Sci 115:10088–10093PubMedPubMedCentralCrossRef
271.
Ekman AK, Bivik Eding C, Rundquist I, Enerbäck C (2019) IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis. J Invest Dermatol 139:1564–73.e8PubMedCrossRef
272.
Ni X, Xu Y, Wang W, Kong B, Ouyang J, Chen J et al (2022) IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation. Nat Immunol 23:1577–1587PubMedPubMedCentralCrossRef
273.
Srivastava A, Luo L, Lohcharoenkal W, Meisgen F, Pasquali L, Pivarcsi A, Sonkoly E (2021) Cross-talk between IFN-γ and TWEAK through miR-149 amplifies skin inflammation in psoriasis. J Allergy Clin Immunol 147:2225–2235PubMedCrossRef
274.
Sidler D, Wu P, Herro R, Claus M, Wolf D, Kawakami Y et al (2017) TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. Nat Commun 8:15395PubMedPubMedCentralCrossRef
275.
Chen X, Takai T, Xie Y, Niyonsaba F, Okumura K, Ogawa H (2013) Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochem Biophys Res Commun 433:532–537PubMedCrossRef
276.
Lou F, Sun Y, Xu Z, Niu L, Wang Z, Deng S et al (2020) Excessive polyamine generation in keratinocytes promotes self-RNA sensing by dendritic cells in psoriasis. Immunity 53:204–16.e10PubMedCrossRef
277.
Funakoshi A, Tatsuno K, Shimauchi T, Fujiyama T, Ito T, Tokura Y (2019) Cholecystokinin downregulates psoriatic inflammation by its possible self-regulatory effect on epidermal keratinocytes. J Immunol 202:2609–2615PubMedCrossRef
278.
Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB (2005) Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 124:1275–1283PubMedCrossRef
279.
Li Q, Ke F, Zhang W, Shen X, Xu Q, Wang H et al (2011) Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice. PLoS ONE 6:e16483PubMedPubMedCentralCrossRef
280.
Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2013) NF-κB: an essential transcription factor in psoriasis. J Dermatol Sci 69:89–94PubMedCrossRef
281.
Pauls K, Schön M, Kubitza RC, Homey B, Wiesenborn A, Lehmann P et al (2001) Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 117:569–575PubMedCrossRef
282.
Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L (1985) Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 230:669–672PubMedCrossRef
283.
Miura H, Sano S, Higashiyama M, Yoshikawa K, Itami S (2000) Involvement of insulin-like growth factor-I in psoriasis as a paracrine growth factor: dermal fibroblasts play a regulatory role in developing psoriatic lesions. Arch Dermatol Res 292:590–597PubMedCrossRef
284.
Gubán B, Vas K, Balog Z, Manczinger M, Bebes A, Groma G et al (2016) Abnormal regulation of fibronectin production by fibroblasts in psoriasis. Br J Dermatol 174:533–541PubMedCrossRef
285.
Angiolilli C, Leijten EFA, Bekker CPJ, Eeftink E, Giovannone B, Nordkamp MO et al (2022) ZFP36 family members regulate the proinflammatory features of psoriatic dermal fibroblasts. J Investig Dermatol 142:402–413PubMedCrossRef
286.
Glowacka E, Lewkowicz P, Rotsztejn H, Zalewska A (2010) IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 55:254–260PubMedCrossRef
287.
288.
Mercurio L, Failla CM, Capriotti L, Scarponi C, Facchiano F, Morelli M et al (2020) Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses. PLoS ONE 15:e0222969PubMedPubMedCentralCrossRef
289.
Gangwar RS, Gudjonsson JE, Ward NL (2022) Mouse models of psoriasis: a comprehensive review. J Investig Dermatol 142:884–897PubMedCrossRef
290.
291.
Farrera C, Melchiotti R, Petrov N, Weng Teng KW, Wong MT, Loh CY et al (2020) T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. J Allergy Clin Immunol 145:1021–5.e15PubMedCrossRef
292.
Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T et al (2019) Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun 10:4703PubMedPubMedCentralCrossRef
293.
Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C et al (2018) The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol 138:1311–1317PubMedCrossRef
294.
He H, Bissonnette R, Wu J, Diaz A, Saint-Cyr Proulx E, Maari C et al (2021) Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol 147:199–212PubMedCrossRef
295.
Tsoi LC, Patrick MT, Shuai S, Sarkar MK, Chi S, Ruffino B et al (2022) Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents. J Allergy Clin Immunol 149:640–9.e5PubMedCrossRef
296.
Swindell WR, Sarkar MK, Liang Y, Xing X, Gudjonsson JE (2016) Cross-disease transcriptomics: unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature. J Invest Dermatol 136:1820–1830PubMedPubMedCentralCrossRef
297.
Nakamizo S, Dutertre CA, Khalilnezhad A, Zhang XM, Lim S, Lum J, Koh G, Foong C, Yong PJA, Tan KJ, Sato R, Tomari K, Yvan-Charvet L, He H, Guttman-Yassky E, Malleret B, Shibuya R, Iwata M, Janela B, Goto T, Lucinda TS, Tang MBY, Theng C, Julia V, Hacini-Rachinel F, Kabashima K, Ginhoux F (2021) Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis. J Exp Med 218(9):e20202345. https://​doi.​org/​10.​1084/​jem.​20202345. Epub 2021 Jul 19CrossRefPubMedPubMedCentral
298.
Gao Y, Yao X, Zhai Y, Li L, Li H, Sun X et al (2021) Single cell transcriptional zonation of human psoriasis skin identifies an alternative immunoregulatory axis conducted by skin resident cells. Cell Death Dis 12:450PubMedPubMedCentralCrossRef
299.
300.
Zhang B, Roesner LM, Traidl S, Koeken V, Xu CJ, Werfel T, Li Y (2023) Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. Allergy 78:439–453PubMedCrossRef
301.
Liu Y, Wang H, Taylor M, Cook C, Martínez-Berdeja A, North JP et al (2022) Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Sci Immunol 7:eabl9165PubMedPubMedCentralCrossRef
302.
Bellinato F, Gisondi P, Girolomoni G (2022) Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis. J Am Acad Dermatol 86:86–96PubMedCrossRef
303.
Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K et al (2021) Potent but transient immunosuppression of T-cells is a general feature of CD71(+) erythroid cells. Commun Biol 4:1384PubMedPubMedCentralCrossRef
304.
Grzywa TM, Nowis D, Golab J (2021) The role of CD71(+) erythroid cells in the regulation of the immune response. Pharmacol Ther 228:107927PubMedCrossRef
305.
Chen L, Li J, Zhu W, Kuang Y, Liu T, Zhang W et al (2020) Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front Microbiol 11:589726PubMedPubMedCentralCrossRef
Metadata
Title
The Immunology of Psoriasis—Current Concepts in Pathogenesis
Authors
Izabela Sieminska
Monika Pieniawska
Tomasz M. Grzywa
Publication date
20-04-2024
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-024-08991-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits